RxDoctor Payments Data

Vishal Parikh, MD

Cardiovascular Disease · Rochester, NYNPI 1770840969

Payments from drug & device makers

$153,852in general payments, 2019–2025

Across 632 payments — averaging $243.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$70K
  • AstraZeneca$27K
  • Lilly USA, LLC$16K
  • Bayer$15K
  • E.r. Squibb & Sons, L.L.C.$13K
  • Actelion Pharmaceuticals US, Inc.$3K
  • plus $9K from 27 others

What the payments were for

  • Consulting fees$2,2502%
  • Speaking & faculty fees$118,62084%
  • Travel & lodging$5,9234%
  • Food & beverage$13,3539%
  • Education$5220%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$153,852 in reported general payments places this provider in the 90th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$62,501
Medicare patients
158
Services billed
526

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis40$1,440,231
Tyvaso DpiTreprostinil14$330,761
EntrestoSacubitril/Valsartan184$224,898
JardianceEmpagliflozin166$203,107
OzempicSemaglutide35$48,157
FarxigaDapagliflozin Propanediol29$33,065
EliquisApixaban23$27,484
MounjaroTirzepatide13$13,867
Repatha SureclickEvolocumab21$11,140
Midodrine Hcl53$7,628
Torsemide120$2,988
Spironolactone207$2,352
Metoprolol Succinate59$1,201
Digoxin40$1,013
Atorvastatin Calcium38$982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$180$1,467,71463 claims
NovartisEntresto$948$224,898184 claims
Boehringer IngelheimJardiance$70,373$203,107166 claims
Novo NordiskOzempic$302$48,15735 claims
AstraZenecaFarxiga$27,158$33,06529 claims
Lilly USA, LLCMounjaro$15,812$13,86713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →